TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal allograft recipients were eligible to participate in the study if they were aged ≥ 18 years, had no previous history of organ transplantation and were not currently using steroids or other immunosuppressants.~Exclusion Criteria:~* Diabetes before transplantation~* Severe metabolic or infectious disease~* Hepatic disease~* Congestive heart failure (New York Heart Association II-IV)~* Cadaver donor kidney donor transplantation~* Unstable condition of the transplanted kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Present with moderate-to-severe chronic plaque psoriasis based on a diagnosis of chronic psoriasis for at least 6 months before baseline.~* Participants who are candidates for systemic therapy and who are naive to systemic treatment for psoriasis.~* Have a (PASI score \>10 or BSA \>10) and DLQI \>10 at screening and at baseline.~Exclusion Criteria:~* Have predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.~* Have received systemic nonbiologic psoriasis therapy.~* Have prior, concurrent, or recent use of ixekizumab or any other biological psoriasis therapy.~* Have any condition or contraindication as addressed in the local labeling for MTX or FAE.~* Presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric disorders or abnormal laboratory values at screening.~* Have severe gastrointestinal disease, oral ulcer, or known, active gastrointestinal ulcer.~* Have had a serious infection or are immunocompromised.~* At screening, participants with significant, present, or early liver disease, e.g., explained by alcohol consumption or hepatic insufficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): 160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks.
- Fumaric Acid Esters (Type: ACTIVE_COMPARATOR): Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.
- Methotrexate (Type: ACTIVE_COMPARATOR): 7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis~* Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia or rigidity~* Parkinson's disease impairment warranting treatment with a levodopa formulation according to the investigator's assessment~Exclusion Criteria:~* History, signs or symptoms suggesting the diagnosis of atypical or secondary Parkinsonism due to drugs, metabolic disorders, encephalitis or other neurodegenerative diseases~* History of stereotaxic brain surgery for PD (e.g., pallidotomy, deep brain stimulation, tissue transplant)~* Diagnosis of Parkinson's disease for more than 5 years prior to Screening~* Previous use of levodopa in any formulation, entacapone or tolcapone for more than 30 days or anytime within 4 weeks (28 days) prior to baseline~* Use of a dopamine agonist within 4 weeks (28 days) prior to baseline

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Female or male aged 18 to 65 years, inclusively, at the time of enrolment.~3. General good health~4. Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not more than twice weekly)~5. Positive skin-prick test to at least one common aeroallergen~Exclusion Criteria:~1. Current lung disease other than mild allergic asthma~2. Any history or symptoms of disease, including, but not limited to, cardiovascular, neurologic, autoimmune or haematologic~3. Any clinically significant abnormal findings in laboratory test results in complete blood count, coagulation, chemistry panel and urinalysis at enrolment and during screening period~4. History of anaphylaxis to any biologic therapy or vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Benralizumab (Type: EXPERIMENTAL): Benralizumab administered subcutaneously
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative colitis~* Adult~* In remission~* Required corticosteroids to induce remission~* Able to make food choices and follow diet~Exclusion Criteria:~* Not able to make food choices

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carrageenan-free diet with placebo (Type: EXPERIMENTAL): This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
- carrageenan-free diet w/ carrageenan (Type: ACTIVE_COMPARATOR): The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma in first or second complete or partial remission~* \>= 4 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade were not considered prior chemotherapy for the purpose of this study)~* Recovered from all acute toxic effects of prior chemotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* White Blood Cell count (WBC) \> 2.5\*10\^9/L~* Absolute polymorphonuclear leukocytes (PMN) count \> 1.5\*10\^9/L~* Platelet (PLT) \> 100\*10\^9/L~* Serum creatinine \<=2.2 mg/dL~* Cardiac and pulmonary status sufficient to undergo apheresis and transplantation~* Negative for HIV~Exclusion Criteria):~* Failed previous stem cell collection~* Previous stem cell transplantation~* Brain metastases or myelomatous meningitis~* Radiation to ≥ 50% of the pelvis~* Abnormal electrocardiogram (ECG) with rhythm disturbance (ventricular arrhythmias) or other conduction abnormality~* Received bone-seeking radionuclides (e.g. holmium)~* A residual acute medical condition resulting from prior chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF plus plerixafor (Type: EXPERIMENTAL): None
- G-CSF plus placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Age: Greater than 18 and less than 45 years.~Number: 44 completed studies (22 placebo, 22 Salsalate).~Sex: 22 Males and 22 Females.~BMI: Greater than or equal to 30 kg.m(2)~EXCLUSION CRITERIA:~* Age below 18 or above 45 years to minimize the risk of glucose clamp.~* Diabetes mellitus (as per 75 g OGTT, WHO 1999 criteria)~* Cardiovascular disease including: abnormal EKG, personal history of coronary heart disease;symptomatic angina pectoris or cardiac insufficiency as defined by NYHA; classification as functional class III or IV.~* Systolic blood pressure greater than 160mmHG and/or diastolic blood pressure greater than 100 mmHg and/or on antihypertensive therapy or resting heart rate greater than 90 bpm.~* Hematological disorder, including prolonged prothrombin time (normal range 10.9-12.9 sec) and partial thromboplastin time (24-36 sec) and thrombocytopenia (less than 150,000 mm(3)).~* Respiratory disease (including influenza, asthma)~* Allergies (including hay fever)~* Gastrointestinal (including peptic ulcer), hepatic or renal disease (ALT and AST greater than 3-fold above upper limit of normal range, creatinine greater than 1.3 mg/dl).~* Alcoholism, alcohol-induced autonomic neuropathy.~* Any endocrinological disorder, including hypopituitarism/pituitary dysfunctions or lesions, hypo/hyperthyroidism, insulinoma.~* CNS disease~* Psychosis or personal history of any psychiatric disorder.~* Taking medications within one month prior to beginning the study, including medications known to have pharmacological interactions with salicylates or that may affect insulin sensitivity and secretion (including salicylates, COX 1 and COX 2 inhibitors, warfarin, Beta-Blockers, phenothiazines, antidepressants, antiarrhythmic drugs, antimuscarinic drugs).~* Acute inflammation as assessed by history, physical and laboratory examination (subjects with C-reactive protein 2 standard deviations above the population mean will not be admitted). The population mean was calculated from subjects admitted at our research unit.~* Pregnant or lactating females or females on hormonal contraceptives.~* History of metabolic acidosis.~* Allergy to aspirin, other salicylates, or bleeding diathesis or currently on oral anticoagulants.~* Any current viral illness.~* Active cancer within 5 years prior to screening for the study.~* Positive urine drug screening test.~* Inability to provide informed consent.~* Smokers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Salsalate (Type: EXPERIMENTAL): Salsalate (3g/day) for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bleach Bath Treatment of Adults With Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe Atopic dermatitis: Eczema Area and Severity Index (EASI) score ≥ 10.~* Skin culture positive for Staphylococcus aureus~* Must have active skin disease on the day of enrollment.~Exclusion Criteria:~* Unwillingness or inability to complete informed consent~* Lidocaine or Novocain allergy~* History of keloid formation~* Course of systemic antibiotics or antivirals within 2 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dilute bleach bath (Type: EXPERIMENTAL): Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
The key inclusion and exclusion criteria include but are not limited to the following:~Inclusion Criteria:~* Has underlying chronic conditions but assessed to be stable as per investigator~* Has ability to complete electronic Vaccine Report Card (eVRC) data collection without assistance as per investigator~Exclusion Criteria:~* Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 1 (Day 1)~* Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease~* Has a coagulation disorder contraindicating intramuscular vaccination~* Has a recent illness with fever~* Has a known malignancy that is progressing or has required active treatment \<3 years before enrollment~* Is expected to receive any pneumococcal vaccine during the study outside of the protocol~* Has received systemic corticosteroids for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine~* Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease~* Has received any non-live vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of study vaccine~* Has received any live vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live vaccine ≤30 days after receipt of study vaccine~* Has received a blood transfusion or blood products, including immunoglobulins ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of study vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- V116 Lot 1 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
- V116 Lot 2 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
- V116 Lot 3 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
- PPSV23 (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~* Subjects with documented clinical diagnosis of diabetic macular edema (DME) with proliferative or non proliferative diabetic retinopathy.~* Subjects, who according to the clinical assessment of the investigator, may benefit from anti-VEGF therapy including those subjects who were participating in the A5751013 study and who, in the investigator's opinion, may benefit from continued pegaptanib sodium therapy.~Exclusion Criteria:~* Eyes with prior scatter (panretinal) photocoagulation within 4 months prior to baseline or anticipated scatter (panretinal) photocoagulation within the next 6 months.~* Presence of any abnormality that is likely to confound assessment of visual acuity improvement in eyes in which macular edema resolves, or improves, such as non-perfusion for \>1 disc area involving the foveal avascular zone (FAZ - involving 2 or more quadrants centered around the foveal avascular zone), epiretinal membrane associated with signs of contraction and/or significant opacification (i.e. striae within 1 disc diameter of the foveal center), or presence of chorioretinal atrophy involving the center of the macula.~* Vitreomacular traction determined clinically and/or by optical coherence tomography (OCT), which, in the investigator's opinion, contributes to the macular edema (or causes associated foveal detachment), and would preclude improvement with pegaptanib sodium.~* Any other cause of macular edema such as vitreous extension, or entrapment to anterior segment wound, or any retinal vein occlusion involving the macula.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pegaptanib sodium arm (Type: EXPERIMENTAL): all patients will receive pegaptanib sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Conservative Treatment of Postprostatectomy Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Involuntary loss of urine that started immediately after radical prostatectomy and has persisted for at least one year.~2. One-week bladder diary with interpretable data and at least two incontinence episodes~Exclusion Criteria:~1. Any unstable medical condition, particularly decompensated congestive heart failure, history of malignant arrhythmias, or unstable angina~2. Cardiac pacemaker or implanted cardiac defibrillator~3. Current use of anticholinergic agents for detrusor instability~4. Folstein's Mini-Mental State Exam score below 24 (impaired mental status)~5. One-week bladder diary with continual leakage - defined as always being damp or wet or unable to quantitate individual accidents.~6. Poorly controlled diabetes, defined as (glycosylated hemoglobin \> 9 within last 3 months).~7. Hematuria on microscopic examination. Enrollment will be permitted after urologic evaluation.~8. Urodynamic evaluation: Post-void residual volume greater than 200 mL

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Behavioral Therapy (Type: EXPERIMENTAL): Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
- Behavioral Therapy Plus Technologies (Type: EXPERIMENTAL): Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
- Placebo Comparator (Type: PLACEBO_COMPARATOR): No treatment control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlates of GERD Symptom Severity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults ages 21-70 years old~* Heartburn symptoms 3 or more days per week with an average daily symptom severity of 3 or more on a 7 day baseline symptom diary~* English language proficiency~* Willingness to be videotaped and connected to physiologic monitoring devices during the visit~Exclusion Criteria:~* Diagnosis of Crohn's disease, systemic sclerosis, known active ulcer disease, gastric cancer, or untreated/active Barrett's esophagitis based on subject self-report and/or medical record review~* Heavy alcohol use (\> 6 drinks/week for women and \> 13 drinks/week for men)~* Pregnant women.~* Dementia or significant memory difficulties~* Severe, unstable psychiatric disease~* Greater than 15 doses of nonsteroidal anti-inflammatory drugs (NSAIDS) within the prior 30 days (aspirin ≤ 325 mg daily permitted) or ongoing NSAID use at a level deemed likely to interfere with the study~* Failure to complete the baseline symptom diary for at least 6 of 7 days~* Change in GERD treatment regimen within the last 2 weeks (subjects may use antacids, H2 receptor blockers, and/or proton pump inhibitors as long as they are symptomatic on a stable regimen)~* Allergy to adhesives~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GERD Patients (Type: None): Subjects with active GERD symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete